Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 2. P. 34–43

A.S. Abdujapparov, S.I. Tkachev, V.A. Aliev, D.S. Romanov, A.V. Nazarenko, Yu.A. Barsukov, T.N. Borisova, V.V. Glebovskaya

Immediate Results of a Prolonged Course of Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer: a Comparison of Classical and Hypofractional Regimes

N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract

Purpose: To compare the effectiveness of the hypofractional and classical modes of radiation therapy in a neoadjuvant prolonged course of chemoradiotherapy for patients with locally advanced rectal cancer (LARC).

Material and methods: This work is based on a retrospective analysis of the database of patients with LARC, who from 2013 to 2017 underwent a prolonged course of neoadjuvant chemoradiotherapy with subsequent surgical intervention. Patients were divided into two groups: the first (main) group, 71 patients with LARC, who, as part of the neoadjuvant treatment, underwent a course of chemoradiotherapy (CRT) in the hypofractionation mode (4 Gy, 3 fractions per week, 32 Gy to regional lymph nodes pelvis and up to 40 Gy to the primary tumor) in combination with chemotherapy with capecitabine 1650 mg/m2 in two doses daily on weekdays. The second group (control group) included 79 patients with LARC, who underwent CRT in the classical fractionation regimen (2 Gy, 5 fractions per week, 44 Gy to regional pelvic lymph nodes and up to 50–58 Gy to the primary tumor) in combination with capecitabine chemotherapy 1650 mg/m2 in two doses on the days of radiation therapy.

Results: The average duration of a prolonged course of CRT in the main group was 22.56 (95 % CI from 21.94 to 23.18) calendar days, in the control group — 38.84 (95 % CI from 38.12 to 39.54), p = 0.0001. Pathological response of the III degree in the main group was recorded in 23 % of cases, and of the IV degree in 18 %, in the control group these indicators were 19 % and 15 %, respectively, p = 0.4. A decrease in the stage of the tumor process was recorded in 50 (70.4 %) cases in the main group and in 47 (59.5 %) cases in the control group, p = 0.16. No statistically significant differences were observed in the incidence and severity of cases of hematological and local toxicity.

Conclusion: The results of our study confirm that the use of a prolonged course of neoadjuvant chemoradiotherapy in hypofractionation mode does not worsen oncological results, does not increase the frequency and severity of early and late radiation injuries, but at the same time reduces the duration of the course of treatment by two weeks. The hypofractionation regimen can be considered as an alternative and not inferior to the classical regimen in the neoadjuvant course of CRT of patients with LARC.

Key words: neoadjuvant chemoradiotherapy, locally advanced rectal cancer, hypofractional regimen, prolonged course

For citation: Abdujapparov AS, Tkachev SI, Aliev VA, Romanov DS, Nazarenko AV, Barsukov YuA, Borisova TN, Glebovskaya VV. Immediate Results of a Prolonged Course of Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer: a Comparison of Classical and Hypofractional Regimes. Medical Radiology and Radiation Safety. 2020;65(2):34-43. (In Russ.).

DOI: 10.12737/1024-6177-2020-65-2-34-43

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. DOI: 10.3322/caac.21492.
2. Каприн АД, Старинский ВВ, Петрова ГВ. Злокачественные новообразования в России в 2016 г. (заболеваемость и смертность). Москва. 2018. 250 c. [Kaprin AD, Starinsky VV, Petrova GV. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow: P.A. Herzen MCRI, 2018. 250 p. (in Russ.)].
3. MacFarlane J, Ryall R, Heald R. Mesorectal excision for rectal cancer. Lancet. 1993;341(8843):457-60. DOI: 10.1016/0140-6736(93)90207-W.
4. Enker W, Thaler H, Cranor M, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg. 1995;181(4):335-46.
5. Bosset J, Collette L, Calais G, Mineur L, Maingon P. Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-23. DOI: 10.1056/NEJMoa060829.
6. Gérard J, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin M, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in t3–4 rectal cancers: results of ffcd 9203. J Clin Oncol. 2006;24(28):4620-5. DOI: 10.1200/JCO.2006.06.7629.
7. Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Mar;15(3):370-98. DOI: 10.6004/jnccn.2017.0036.
8. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-40. DOI: 10.1056/NEJMoa040694.
9. Maas M, Nelemans P, Valentini V, Das P, Rödel C, Kuo L, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835-44. DOI: 10.1016/S1470-2045(10)70172-8.
10. Stipa F, Chessin D, Shia J, Paty P, Weiser M, Temple L, et al. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol. 2006;13(8):1047-53. DOI: 10.1245/ASO.2006.03.053.
11. Fernandez-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CapOх) compared with induction CapOх followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: grupo cancer de recto 3 study. J Clin Oncol. 2010;28(5):859-65. DOI: 10.1200/JCO.2009.25.8541.
12. Deutsche Krebsgesellschaft, Deutsche Krebshilfe (Leitlinienprogramm Onkologie). Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.0 AWMF); 2018. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ (date of request 03.10.2019).
13. Engstrom PF, Arnoletti JP, Benson AB 3rd, Berlin JD, Berry JM, Chen YJ, et al. NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw. 2010;8:106-20. DOI: 10.6004/jnccn.2010.0007.
14. Viani GA, Viana BS, Martin JEC, Rossi BT, Zuliani G, Stefano EJ. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial. Cancer. 2016;122:2004-11. DOI: 10.1002/cncr.29983.
15. Kwak Y-K, Lee S-W, Kay CS, Park HH. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose. PLoS One. 2017;12:e0183339. DOI: 10.1371/journal.pone.0183339.
16. Huang C-M, Huang M-Y, Tsai H-L, Huang C-W, Ma C-J, Lin C-H, et al. A retrospective comparison of outcome and toxicity of preoperative image-guided intensity-modulated radiotherapy versus conventional pelvic radiotherapy for locally advanced rectal carcinoma. J Radiat Res. 2017;58:247-59. DOI: 10.1093/jrr/rrw087.
17. Simson DK, Mitra S, Ahlawat P, Saxena U, Sharma MK, Rawat S, et al. Prospective study of neoadjuvant chemoradiotherapy using intensity-modulated radiotherapy and 5 fluorouracil for locally advanced rectal cancer — toxicities and response assessment. Cancer Manag Res. 2018;10:519-26. DOI: 10.2147/CMAR.S142076.
18. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Rectal Cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16:874-901. DOI: 10.6004/jnccn.2018.0061.
19. Emmertsen KJ, Laurberg S. Bowel dysfunction after treatment for rectal cancer. Acta Oncol. 2008;47:994-1003. DOI: 10.1080/02841860802195251.
20. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients – a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199-206. DOI: 10.1200/JCO.2005.14.779.
21. Dapper H, Rodríguez I, Münch S, Peeken JC, Borm K, Combs SE, et al. Impact of VMAT-IMRT compared to 3D conformal radiotherapy on anal sphincter dose distribution in neoadjuvant chemoradiation of rectal cancer. Radiat Oncol. 2018;13:237. DOI: 10.1186/s13014-018-1187-7.
22. Hartley A, Ho KF, McConkey C, Geh JI. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. The British Institute of Radiology. 2014. DOI: 10.1259/bjr/86650067.
23. Costi R, Leonardi F, Zanoni D, Violi V, et al. Palliative care and end-stage colorectal cancer management: The surgeon meets the oncologist. World J Gastroenterol. 2014;20:7602-21. DOI: 10.3748/wjg.v20.i24.7602.
24. Wen G, Zhang J, Chi F, Chen L, Huang S, Niu S. Dosimetric Comparison of Volumetric Modulated Arc Therapy (VMAT), 5F Intensity Modulated Radiotherapy (IMRT) and 3D Conformal Radiotherapy (3DCRT) in Rectal Carcinoma Receiving Neoadjuvant Chemoradiotherapy. Int J Med Phys Clin Eng & Radiat Oncol. 2015;04:54-63. DOI: 10.4236/ijmpcero.2015.41008.
25. Roh M, Yothers G, O’Connell M, Beart R, Pitot H, Shieldset A, at al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol. 2011;29(15_suppl):3503-3503. DOI: 10.1200/jco.2011.29.15_suppl.3503.
26. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncology. 2012;13:579-88. DOI: 10.1016/S1470-2045(12)70116-X.
27. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017. July 1;28(suppl_4):iv22–iv40. DOI: 10.1093/annonc/mdx224.
28. Zhou ZR, Liu SX, Zhang TS, Chen LX, Xia J, Hu ZD, et al. Short-course preoperative radiotherapy with immediate surgery versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer: a systematic review and meta-analysis. Surg Oncol 2014;23(4):211-21. DOI: 10.1016/j.suronc.2014.10.003.
29. Liu SX, Zhou ZR, Chen LX, Yang YJ, Hu ZD, Zhang TS. Short-course Versus Long-course Preoperative Radiotherapy plus Delayed Surgery in the Treatment of Rectal Cancer: a Meta-analysis. Asian Pac J Cancer Prev 2015;16(14):5755-62. DOI: 10.7314/apjcp.2015.16.14.5755.
30. Kairevičė L, Latkauskas T, Tamelis A, Petrauskas A, Paužas H, Žvirblis T, et al. Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgery for stage II-III resectable rectal cancer: 5-year survival data of a randomized controlled trial. Medicina (Kaunas) 2017;53(3):150-8. DOI: 10.1016/j.medici.2017.05.006.
31. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012;30(31):3827-33. DOI: 10.1200/JCO.2012.42.9597.
32. Vliegen RF, Beets GL, von Meyenfeldt MF, Kessels AG, Lemaire EE, van Engelshoven JM, et al. Rectal Cancer: MR Imaging in Local Staging — Is Gadolinium-Based Contrast Material Helpful? Radiology. 2005;234(1):179-88. DOI: 10.1148/radiol.2341031403.

PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 28.11.2019.

Accepted for publication: 12.03.2020.